Author

L. Casares

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

A. T. Dinkova-Kostova· 3 shared L. de la Vega· 3 shared M. Higgins· 2 shared T. Honda· 2 shared A. E. Kiib· 1 shared A. Jackson· 1 shared D. Caprioglio· 1 shared D. Olagnier· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCell Biology

A. T. Dinkova-Kostova

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, are potent BACH1 inhibitors

L. Casares, R. Moreno, M. Higgins, S. D. Naidu, G. Neill, L. Cassin, A. E. Kiib, E. B. Svenningsen, T. Honda, T. B. Poulsen, A. T. Dinkova-Kostova, D. Olagnier, L. de la Vega

This study identifies CDDO-derivatives as BACH1 inhibitors, explaining their higher potency as HMOX1 inducers compared to CDDO.

bioRxiv · Oct 29, 2021 · PreprintCell Biology

Isomeric O-methyl cannabidiolquinones with dual BACH1/NRF2 activity

L. Casares, J. D. Unciti, M. E. Prados, D. Caprioglio, M. Higgins, G. Apendino, A. T. Dinkova-Kostova, E. Munoz, L. de la Vega

The paper develops a CBD derivative with dual BACH1 inhibition and NRF2 activation, showing neuroprotection in Huntington's disease cell models.

bioRxiv · Jun 16, 2020Cell Biology

The kinase inhibitor AT9283 selectively kills colorectal cancer cells with hyperactive NRF2

L. Torrente, G. Maan, L. Casares, A. Jackson, T. Honda, G. Wells, E. Kulesskiy, J. Saarela, A. T. Dinkova-Kostova, L. de la Vega

The paper identifies AT9283 as a drug that selectively kills colorectal cancer cells with hyperactive NRF2, showing its potential as a therapeutic target.

bioRxiv · Oct 21, 2019 · PreprintCancer Biology